pembrolizumab for recurrent head and neck squamous cell carcinomas (hnscc)
Published 2 years ago • 221 plays • Length 4:42Download video MP4
Download video MP3
Similar videos
-
6:46
first-line pembrolizumab for recurrent/metastatic head and neck squamous cell carcinoma
-
1:13
keynote-b84: pepinemab pembrolizumab for metastatic/recurrent head & neck squamous cell carcinoma
-
6:35
pembrolizumab as first-line therapy for recurrent/metastatic head and neck cancer
-
5:34
pembrolizumab for recurrent hnscc
-
3:56
phase ii trial of pembrolizumab & cabozantinib in patients with recurrent metastatic hnscc
-
1:36
addition of an egfr/tgfβ inhibitor with pembrolizumab in head and neck cancer
-
3:15
phase ii study of petosemtamab and pembrolizumab for recurrent/metastatic hnscc
-
2:37
pembrolizumab is effective in recurrent, metastatic squamous cell carcinomas of the head and neck
-
6:51
pembrolizumab and nivolumab in recurrent hnscc
-
4:06
immunotherapy for head and neck cancer treatment
-
2:36
ca209-9ky: imrt nivolumab for recurrent head and neck squamous cell cancer
-
0:55
dr. cohen on immunotherapy in head and neck squamous cell carcinoma
-
1:52
safety of bca101, an egfr/tgfβ inhibitor, with pembrolizumab in hnscc
-
3:08
keynote-048: pembrolizumab monotherapy for frontline r/m hnscc
-
2:45
final keynote-048 results with frontline pembrolizumab in recurrent/metastatic hnscc
-
4:03
keynote-040: groundbreaking results for pembrolizumab in head and neck cancer
-
1:58
dr. rischin on keynote-048 results in head and neck squamous cell carcinoma
-
1:41
phase ii trial of pembrolizumab and cabozantinib in hnscc
-
0:51
dr. machiels on pembrolizumab and chemoradiation in hnscc